Literature DB >> 17947463

Genome-wide allelotypes of familial pancreatic adenocarcinomas and familial and sporadic intraductal papillary mucinous neoplasms.

Tadayoshi Abe1, Noriyoshi Fukushima, Kieran Brune, Corinne Boehm, Norihiro Sato, Hiroyuki Matsubayashi, Marcia Canto, Gloria M Petersen, Ralph H Hruban, Michael Goggins.   

Abstract

PURPOSE: Most familial cancer susceptibility genes are tumor suppressor genes that are biallelically inactivated in familial neoplasms through somatic deletion of the wild-type allele. Identifying the genomic losses that occur in pancreatic neoplasms, particularly those that occur in familial and precursor neoplasms, may help localize the genes responsible for pancreatic cancer susceptibility. EXPERIMENTAL
DESIGN: Normal and neoplastic tissue DNA was isolated from fresh-frozen surgically resected tissues from 20 patients with primary familial pancreatic adenocarcinoma (defined as having at least one first-degree relative with pancreatic cancer), 31 with sporadic intraductal papillary mucinous neoplasms (IPMN), and 7 with familial IPMNs using laser capture microdissection. Microdissected DNA was whole genome amplified using multiple strand displacement. Genome-wide allelotypes were determined using 391 microsatellite markers. The accuracy of microdissection and fidelity of the whole genome amplification were determined by comparing the genotypes of microdissected primary pancreatic cancers to the genotypes of xenografts derived from these cancers and by comparing the results of amplified to nonamplified specimens.
RESULTS: The concordance of genotypes between LCM whole genome amplified primary pancreatic cancers and their corresponding pancreatic cancer xenograft DNAs was 98%. Among the 20 primary familial pancreatic adenocarcinomas, we found a high prevalence of loss of heterozygosity (LOH) with an average fractional allelic loss (FAL) of 49.9% of an aggregate of 2,378 informative markers. The level of FAL in the IPMNs (10%) was significantly lower than in the pancreatic adenocarcinomas. The most common locus of LOH in the IPMNs was at 19p (LOH at 24% of markers). The regions of frequent allelic loss observed in the familial pancreatic cancers were similar to those found in sporadic pancreatic cancers.
CONCLUSIONS: The allelic loss patterns of familial and sporadic pancreatic cancers and IPMNs provide clues as to the genomic locations of tumor suppressor genes inactivated in these neoplasms.

Entities:  

Mesh:

Year:  2007        PMID: 17947463     DOI: 10.1158/1078-0432.CCR-07-0471

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

1.  Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Hanno Matthaei; Alexis L Norris; Athanasios C Tsiatis; Kelly Olino; Seung-Mo Hong; Marco dal Molin; Michael G Goggins; Marcia Canto; Karen M Horton; Keith D Jackson; Paola Capelli; Giuseppe Zamboni; Laura Bortesi; Toru Furukawa; Shinichi Egawa; Masaharu Ishida; Shigeru Ottomo; Michiaki Unno; Fuyuhiko Motoi; Christopher L Wolfgang; Barish H Edil; John L Cameron; James R Eshleman; Richard D Schulick; Anirban Maitra; Ralph H Hruban
Journal:  Ann Surg       Date:  2012-02       Impact factor: 12.969

Review 2.  Molecular signatures of pancreatic cancer.

Authors:  Seung-Mo Hong; Jason Y Park; Ralph H Hruban; Michael Goggins
Journal:  Arch Pathol Lab Med       Date:  2011-06       Impact factor: 5.534

3.  Pancreatic cancer DNMT1 expression and sensitivity to DNMT1 inhibitors.

Authors:  Ang Li; Noriyuki Omura; Seung-Mo Hong; Michael Goggins
Journal:  Cancer Biol Ther       Date:  2010-02-01       Impact factor: 4.742

4.  Genome-wide somatic copy number alterations in low-grade PanINs and IPMNs from individuals with a family history of pancreatic cancer.

Authors:  Seung-Mo Hong; Audrey Vincent; Mitsuro Kanda; Julie Leclerc; Noriyuki Omura; Michael Borges; Alison P Klein; Marcia Irene Canto; Ralph H Hruban; Michael Goggins
Journal:  Clin Cancer Res       Date:  2012-06-21       Impact factor: 12.531

5.  Loss of expression of the SWI/SNF chromatin remodeling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Marco Dal Molin; Seung-Mo Hong; Sachidanand Hebbar; Rajni Sharma; Francesca Scrimieri; Roeland F de Wilde; Skye C Mayo; Michael Goggins; Christopher L Wolfgang; Richard D Schulick; Ming-Tseh Lin; James R Eshleman; Ralph H Hruban; Anirban Maitra; Hanno Matthaei
Journal:  Hum Pathol       Date:  2011-09-21       Impact factor: 3.466

6.  Role of cyclooxygenase-2 gene polymorphisms in pancreatic carcinogenesis.

Authors:  Renata Talar-Wojnarowska; Anita Gasiorowska; Marek Olakowski; Pawel Lampe; Beata Smolarz; Hanna Romanowicz-Makowska; Ewa Malecka-Panas
Journal:  World J Gastroenterol       Date:  2011-09-28       Impact factor: 5.742

7.  DNA methylation alterations in endoscopic retrograde cholangiopancreatography brush samples of patients with suspected pancreaticobiliary disease.

Authors:  Mansour A Parsi; Ang Li; Chung-Pin Li; Michael Goggins
Journal:  Clin Gastroenterol Hepatol       Date:  2008-09-05       Impact factor: 11.382

8.  Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Seung-Mo Hong; David Kelly; Margaret Griffith; Noriyuki Omura; Ang Li; Chung-Pin Li; Ralph H Hruban; Michael Goggins
Journal:  Mod Pathol       Date:  2008-09-26       Impact factor: 7.842

Review 9.  Management of mucin-producing cystic neoplasms of the pancreas.

Authors:  Stefan Fritz; Andrew L Warshaw; Sarah P Thayer
Journal:  Oncologist       Date:  2009-02-11

10.  Germline BRCA1 mutations predispose to pancreatic adenocarcinoma.

Authors:  Wigdan Al-Sukhni; Heidi Rothenmund; Ayelet Eppel Borgida; George Zogopoulos; Anne-Marie O'Shea; Aaron Pollett; Steven Gallinger
Journal:  Hum Genet       Date:  2008-09-02       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.